Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nutritional and Metabolic Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    890 result(s) found for: Nutritional and Metabolic Disease. Displaying page 7 of 45.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2015-002963-40 Sponsor Protocol Number: IDAPADM1 Start Date*: 2015-10-26
    Sponsor Name:Dra Cristina Avendaño Sola
    Full Title: Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005242-60 Sponsor Protocol Number: UoL001187 Start Date*: 2016-10-03
    Sponsor Name:University of Liverpool
    Full Title: RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) pati...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003053-34 Sponsor Protocol Number: CRC2014EMPA Start Date*: 2015-02-24
    Sponsor Name:IPPMed – Institut für Pharmakologie und Präventive Medizin GmbH
    Full Title: Randomized, double-blind, placebo controlled, crossover clinical study to analyse the effect of empagliflozin on microvascular circulation
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003788-39 Sponsor Protocol Number: ESR-14-10231 Start Date*: 2014-12-17
    Sponsor Name:Profil Mainz GmbH & Co KG
    Full Title: Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002712-51 Sponsor Protocol Number: 2020 Start Date*: 2021-03-05
    Sponsor Name:Kirsi Pietiläinen
    Full Title: Semaglutide as an adjunct to dieting in the treatment of type 2 diabetes – effects on glucose metabolism, prevention of weight regain and peripheral tissue metabolic activation
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022677-34 Sponsor Protocol Number: EMR200109-619 Start Date*: 2011-09-07
    Sponsor Name:Dekan des Fachbereichs Humanmedizin
    Full Title: Influence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Medical condition: Type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003028-19 Sponsor Protocol Number: PS_KSS_001_2019 Start Date*: 2019-10-30
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome
    Medical condition: Pearson and Kearns-Sayre syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.0 10010331 - Congenital, familial and genetic disorders 10074070 Mitochondrial encephalopathy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003124-16 Sponsor Protocol Number: KH176-204 Start Date*: 2021-01-12
    Sponsor Name:Khondrion B.V.
    Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease.
    Medical condition: Genetically confirmed mitochondrial disease
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002323-35 Sponsor Protocol Number: TAK-669-3001 Start Date*: 2022-11-10
    Sponsor Name: Takeda Development Center Americas, Inc.
    Full Title: A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease
    Medical condition: Type 1 Gaucher Disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005482-12 Sponsor Protocol Number: GLP-1-2012-01 Start Date*: 2013-04-15
    Sponsor Name:University College Dublin
    Full Title: The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003888-56 Sponsor Protocol Number: 20192022 Start Date*: 2021-01-30
    Sponsor Name:Department of Nephrology, Herlev & Gentofte Hospital, Herlev Hospital
    Full Title: Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10060881 Adynamic bone disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000583-34 Sponsor Protocol Number: AGLU03707_MSC12817 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients with Pompe Disease Who Have Previously Received Myozyme
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000530-54 Sponsor Protocol Number: VS56151/17000277 Start Date*: 2018-01-16
    Sponsor Name:University of Copenhagen
    Full Title: The effect of cannibinols in patients with pancreatic cancer in the palliative state
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10037027 Protein-calorie malnutrition LLT
    20.0 100000004861 10064015 Cancer cachexia LLT
    20.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004578-16 Sponsor Protocol Number: VAL-1221-201-16 Start Date*: 2017-06-19
    Sponsor Name:Valerion Therapeutics, LLC
    Full Title: A Three-month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 versus Myozyme®/Lumizyme® in Patien...
    Medical condition: Late-Onset GSD-II (Pompe Disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036143 Pompe's disease LLT
    20.1 100000004850 10045253 Type II glycogen storage disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002154-32 Sponsor Protocol Number: AT2220-010 Start Date*: 2011-12-07
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE
    Medical condition: Pompe Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015114-22 Sponsor Protocol Number: ML22916 Start Date*: 2010-08-10
    Sponsor Name:Roche Pharma AG
    Full Title: A randomized controlled, single-blind, proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progr...
    Medical condition: diabetic and transplanted CKD stage III patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005274-30 Sponsor Protocol Number: UCL_2011_DIDo Start Date*: 2012-08-27
    Sponsor Name:Université catholique de Louvain
    Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study
    Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10007184 CAPD LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000584-14 Sponsor Protocol Number: AGLU03807,MSC12862 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004641-25 Sponsor Protocol Number: 201700823 Start Date*: 2019-04-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation.
    Medical condition: Proteinuric Kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 08:16:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA